Unveiling the role of mast cells in breast cancer–a case study of natural product Eriocalyxin B as an inhibitor

Abstract

<p>Background: Inflammation and breast cancer are closely associated. Considering that mast cells are essential component of inflammatory cells, its relationship with breast cancer arose rising attention. Purpose: This study aims to elucidate the influence of mast cells on triple negative breast cancer (TNBC) and explore potential therapeutic interventions targeting mast cells. Methods: The study employed proteomic analysis and molecular investigations to examine disparities between mast cells from healthy mice and those from breast tumor-bearing mice. Additionally, the natural product Ericalyxin B (Eri B) was utilized for its anti-inflammatory and anti-breast cancer properties. Ex vivo and in vivo treatments of Eri B were conducted to assess its impact on mast cell-mediated promotion of breast cancer. Results: The crosstalk between mast cells and TNBC cells was found to enhance proliferation, invasion, and migration of TNBC cells. Mast cells from breast tumor-bearing mice exhibited disparities compared to those from healthy mice, as confirmed by proteomic analysis. Treatment with Eri B suppressed the promoting effect of mast cells on breast cancer by inhibiting the TAK1/NF-κB signaling pathway and downregulating downstream cytokine release. In vivo treatment with Eri B also reduced mast cell numbers and tryptase levels in tumors. Conclusion: This is the first study to compare disparities between mast cells derived from healthy mice and those from breast tumor-bearing mice, while also revealing the effects of the natural product Eri B on mast cells in breast cancer. Our findings highlighted the crucial role of mast cells as potential targets for triple negative breast cancer therapy and suggests that Eri B holds promise in suppressing breast cancer progression by regulating mast cells. <br></p>